Study of a lipophilic captopril analogue binding to angiotensin I converting enzyme

Journal of Peptide Science

Volumn 16, Issue 2, 2010, Pages 91-97

  Dalkas, Georgios A ^a   Marchand, Damien ^b   Galleyrand, Jean Claude ^b   Martinez, Jean ^b   Spyroulias, Georgios A ^a   Cordopatis, Paul ^a   Cavelier, Florine ^b  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITÉ DE MONTPELLIER   (France)

Author keywords

ACE; Docking simulations; Silacaptopril; Zinc metalloenzyme

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SILACAPTOPRIL; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CRYSTAL STRUCTURE; DRUG PROTEIN BINDING; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME INHIBITION; IC 50; LIPOPHILICITY; MOLECULAR DOCKING; PRIORITY JOURNAL; PROTEIN DOMAIN; SIMULATION; STEREOSPECIFICITY;

CAPTOPRIL; CATALYTIC DOMAIN; COMPUTER SIMULATION; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; MOLECULAR STRUCTURE; ORGANOSILICON COMPOUNDS; PEPTIDYL-DIPEPTIDASE A; PROTEIN BINDING;

EID: 74749098357     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.1201     Document Type: Article

References (32)

1. Hubert C, Houot AM, Corvol P, Soubrier F. Structure of the angiotensin I-converting enzyme gene. Two alternate promoters correspond to evolutionary steps of a duplicated gene. J. Biol. Chem. 1991; 266: 15377-15383.
2. Ehlers MR, Fox EA, Strydom DJ, Riordan JF. Molecular cloning of human testicular angiotensin-converting enzyme: the testis isozyme is identical to the C-terminal half of endothelial angiotens I-inconverting enzyme. Proc. Natl Acad. Sci. USA 1989; 86: 7741-7745.
3. Soubrier F, Alhenc-Gelas F, Hubert C, Allegrini J, John M, Tregear G, Corvol P. Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. Proc. Natl Acad. Sci. USA 1988; 85: 9386-9390.
4. Natesh R, Schwager SL, Sturrock ED, Acharya KR. Crystal structure of the human angiotensin-converting enzyme-lisinopril complex. Nature 2003; 421: 551-554.
5. Watermeyer JM, Sewell BT, Schwager SL, Natesh R, Corradi HR, Acharya KR, Sturrock ED. Structure of testis ACE glycosylation mutants and evidence for conserved domain movement. Biochemistry 2006; 45: 12654-12663.
6. Corradi HR, Schwager SL, Nchinda AT, Sturrock ED, Acharya KR. Crystal structure of the N domain of human somatic angiotensin I-converting enzyme provides a structural basis for domain-specific inhibitor design. J.Mol. Biol. 2006; 357: 964-974.
7. Redelinghuys P, Nchinda AT, Sturrock ED. Development of domain-selective angiotensin I-converting enzyme inhibitors. Ann. N Y Acad. Sci. 2005; 1056: 160-175.
8. Spyroulias GA, Cordopatis P. Current inhibition concepts of zinc metallopeptidases involved in blood pressure regulation. Curr. Enzyme Inhibit. 2005; 1: 29-42.
9. Shapiro R, Holmquist B, Riordan JF. Anion activation of angiotensin converting enzyme: dependence on nature of substrate. Biochemistry 1983; 22: 3850-3857.
10. Papakyriakou A, Spyroulias GA, Sturrock ED, Manessi-Zoupa E, Cordopatis P. Simulated interactions between angiotensin-converting enzyme and substrate gonadotropin-releasing hormone: novel insights into domain selectivity. Biochemistry 2007; 46: 8753-8765.
11. Thorsett ED, Harris EE, Aster SD, Peterson ER, Snyder JP, Springer JP, Hirshfield J, Tristram EW, Patchett AA, Ulm EH, Vassil TC. Conformationally restricted inhibitors of angiotensin converting enzyme: synthesis and computations. J. Med. Chem. 1986; 29: 251-260.
12. Fournie-Zaluski MC, Coric P, Turcaud S, Lucas E, Noble F, Maldonado R, Roques BP. "Mixed inhibitor-prodrug" as a new approach toward systemically active inhibitors of enkephalin-degrading enzymes. J. Med. Chem. 1992; 35: 2473-2481.
13. Roques BP, Noble F, Crine P, Fournie-Zaluski MC. Inhibitors of neprilysin: design, pharmacological and clinical applications. Meth. Enzymol. 1995; 248: 263-283.
14. Wyvratt MJ, Patchett AA. Recent developments in the design of angiotensin-converting enzyme inhibitors. Med. Res. Rev. 1985; 5: 483-531.
15. Ondetti MA, Rubin B, Cushman DW. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science 1977; 196: 441-444.
16. Natesh R, Schwager SL, Evans HR, Sturrock ED, Acharya KR. Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular angiotensin I-converting enzyme. Biochemistry 2004; 43: 8718-8724.
17. Mutahi M, Nittoli T, Guo L, Sieburth SM. Silicon-based metalloprotease inhibitors: synthesis and evaluation of silanol and silanediol peptide analogues as inhibitors of angiotensin-converting enzyme. J. Am. Chem. Soc. 2002; 124: 7363-7375.
18. Cushman DW, Cheung HS, Sabo EF, Ondetti MA. Design of potent competitive inhibitors of angiotensin-converting enzyme. Carboxyalkanoyl and mercaptoalkanoyl amino acids. Biochemistry 1977; 16: 5484-5491.
19. Hanessian S, Reinhold U, Saulnier M, Claridge S. Probing the importance of spacial and conformational domains in captopril analogs for angiotensin converting enzyme activity. Bioorg. Med. Chem. Lett. 1998; 8: 2123-2128.
20. Vivet BCF, Martinez J. Synthesis of silaproline, a new proline surrogate. Eur. J. Org. Chem. 2000; 5: 807-811.
21. Santos RA, Krieger EM, Greene LJ. An improved fluorometric assay of rat serum and plasma converting enzyme. Hypertension 1985; 7: 244-252.
22. Mehanna AS, Dowling M. Liquid chromatographic determination of hippuric acid for the evaluation of ethacrynic acid as angiotensin converting enzyme inhibitor. J. Pharm. Biomed. Anal. 1999; 19: 967-973.
23. Case DADT, Cheatham TE III, Simmerling CL, Wang J, Duke RE, Luo R, Merz KM Jr, Pearlman DA, Crowley M, Walker RC, Zhang W, Wang B, Hayik S, Roitberg A, Seabra G, Wong KF, Paesani F, Wu X, Brozell S, Tsui V, Gohlke YL, Tan CH, Mongan J, Hornak V, Cui G, Beroza P, Mathews DH, Schafmeister C, Ross WS, Kollman PA. AMBEP 9. University of California: San Francisco, 2006.
24. Bashford D, Karplus M. pKa's of ionizable groups in proteins: atomic detail from a continuum electrostatic model. Biochemistry 1990; 29: 10219-10225.
25. Tsui VCD. Theory and applications of the generalized Born solvation model in macromolecular simulations. Biopolymers 2001; 56: 275-291.
26. Jakalian A, Jack DB, Bayly CI. Fast, efficient generation of high-quality atomic charges. AM1-BCCmodel: II. Parameterization and validation. J. Comput. Chem. 2002; 23: 1623-1641.
27. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998; 19: 1639-1662.
28. Vivet B, Cavelier F, Martinez J, Didierjean C, Marraud M, Aubry A. A silaproline-containing dipeptide. Acta Crystallogr. C 2000; 56: 1452-1454.
29. Cavelier F, Vivet B, Martinez J, Aubry A, Didierjean C, Vicherat A, Marraud M. Influence of silaproline on peptide conformation and bioactivity. J. Am. Chem. Soc. 2002; 124: 2917-2923.
30. Cavelier F, Marchand D, Martinez J, Sagan S. Biological activity of silylated amino acid containing substance P analogues. J. Pept. Res. 2004; 63: 290-296.
31. Nam DH, Lee CS, Ryu DD. An improved synthesis of captopril. J. Pharm. Sci. 1984; 73: 1843-1844.
32. Schechter I, Berger A. On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. 1967; 27: 157-162.